Edwards Lifesciences Profit Margin 2010-2022 | EW

Current and historical gross margin, operating margin and net profit margin for Edwards Lifesciences (EW) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Edwards Lifesciences net profit margin as of September 30, 2022 is 27.2%.
Edwards Lifesciences Annual Profit Margins
Edwards Lifesciences Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $46.932B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.645B 22.45
Alcon (ALC) Switzerland $33.321B 28.69
STERIS (STE) Ireland $18.019B 22.42
Teleflex (TFX) United States $10.587B 17.18
Fresenius Medical Care AG KGaA (FMS) Germany $8.996B 9.03
Penumbra (PEN) United States $7.452B 1783.82
Globus Medical (GMED) United States $7.103B 36.11
Integer Holdings (ITGR) United States $2.367B 19.00
Glaukos (GKOS) United States $2.263B 0.00
Nevro (NVRO) United States $1.556B 0.00
Paragon 28 (FNA) United States $1.534B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.246B 17.74
Artivion (AORT) United States $0.520B 0.00